Cell–cell fusion is also a prominent feature of bladder cancer in vitro, contributing to immune evasive properties [25], and interestingly, a study reported expression-promoting mutations in the Syncytin-1 3′-LTR in ~85% of tissue samples from patients with bladder cancer [26]. The gene discussed is ERVW-1; the disease is urinary bladder carcinoma.